Trial Profile
A Randomized, Double Blind, Placebo Controlled, Four Way Crossover Study To Determine The Effects Of PF-03654764 +/- Allegra (Fexofenadine) On Symptoms Of Allergic Rhinitis In Subjects Exposed To Ragweed Pollen In An Environmental Exposure Unit.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2010
Price :
$35
*
At a glance
- Drugs PF 3654764 (Primary) ; Fexofenadine; Fexofenadine/pseudoephedrine
- Indications Allergic rhinitis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 03 Aug 2010 Additional trial location [Canada] identified as reported by ClinicalTrials.gov.
- 03 Aug 2010 Actual initiation date added to 1 Jan 2010 as reported by ClinicalTrials.gov.
- 03 Aug 2010 Actual end date added to 1 May 2010 as reported by ClinicalTrials.gov.